US 2026/0308240 A1Published application

Antibody targeting dll3 and use of antibody

AssigneeNeukio Biotherapeutics (Shanghai) Co., Ltd.

InventorsTing LONG, Lei ZHANG, Liqun Richard WANG

Life of this patent

Estimating the term…

Abstract

An antibody or an antigen-binding fragment targeting DLL3 and a method of using the antibody are disclosed. The DLL3 antibody shows excellent specificity and binding capacity, a chimeric antigen receptor derived therefrom shows excellent killing capacity against tumor cells, the cytotoxicity of the DLL3 antibody is low, and its side effects are low.

Claims19

Dependent claims

A DLL3-targeting antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, and wherein the heavy chain variable region and light chain variable region comprise complementarity determining regions (CDRs) selected from the group consisting of:

(1) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
37,
HCDR2 set forth in SEQ ID NO:
38, and
HCDR3 set forth in SEQ ID NO:
39;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
40,
LCDR2 set forth in SEQ ID NO:
41, and
LCDR3 set forth in SEQ ID NO:
42;
or
(2) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
7,
HCDR2 set forth in SEQ ID NO:
8, and
HCDR3 set forth in SEQ ID NO:
9;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
10,
LCDR2 set forth in SEQ ID NO:
11, and
LCDR3 set forth in SEQ ID NO:
12;
or
(3) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
19,
HCDR2 set forth in SEQ ID NO:
20, and
HCDR3 set forth in SEQ ID NO:
21;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
22,
LCDR2 set forth in SEQ ID NO:
23, and
LCDR3 set forth in SEQ ID NO:
24;
or
(4) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
31,
HCDR2 set forth in SEQ ID NO:
32, and
HCDR3 set forth in SEQ ID NO:
33;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
34,
LCDR2 set forth in SEQ ID NO:
35, and
LCDR3 set forth in SEQ ID NO:
36;
or
(5) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
25,
HCDR2 set forth in SEQ ID NO:
26, and
HCDR3 set forth in SEQ ID NO:
27;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
28,
LCDR2 set forth in SEQ ID NO:
29, and
LCDR3 set forth in SEQ ID NO:
30;
or
(6) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
1,
HCDR2 set forth in SEQ ID NO:
2, and
HCDR3 set forth in SEQ ID NO:
3;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
4,
LCDR2 set forth in SEQ ID NO:
5, and
LCDR3 set forth in SEQ ID NO:
6;
or
(7) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
13,
HCDR2 set forth in SEQ ID NO:
43, and
HCDR3 set forth in SEQ ID NO:
33;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
44,
LCDR2 set forth in SEQ ID NO:
35, and
LCDR3 set forth in SEQ ID NO:
36;
or
(8) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
13,
HCDR2 set forth in SEQ ID NO:
14, and
HCDR3 set forth in SEQ ID NO:
15;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
16,
LCDR2 set forth in SEQ ID NO:
17, and
LCDR3 set forth in SEQ ID NO:
18;
wherein the CDR sequences are identified based on the Kabat numbering scheme;
or
the heavy chain variable region and light chain variable region of the antibody or antigen-binding fragment thereof comprise complementarity determining regions (CDRs) selected from the group consisting of:
(1) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
56,
HCDR2 set forth in SEQ ID NO:
57, and
HCDR3 set forth in SEQ ID NO:
39;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
40,
LCDR2 set forth in SEQ ID NO:
41, and
LCDR3 set forth in SEQ ID NO:
42;
or
(2) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
47,
HCDR2 set forth in SEQ ID NO:
48, and
HCDR3 set forth in SEQ ID NO:
9;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
10,
LCDR2 set forth in SEQ ID NO:
11, and
LCDR3 set forth in SEQ ID NO:
12;
or
(3) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
50,
HCDR2 set forth in SEQ ID NO:
51, and
HCDR3 set forth in SEQ ID NO:
21;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
22,
LCDR2 set forth in SEQ ID NO:
23, and
LCDR3 set forth in SEQ ID NO:
24;
or
(4) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
54,
HCDR2 set forth in SEQ ID NO:
55, and
HCDR3 set forth in SEQ ID NO:
33;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
34,
LCDR2 set forth in SEQ ID NO:
35, and
LCDR3 set forth in SEQ ID NO:
36;
or
(5) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
52,
HCDR2 set forth in SEQ ID NO:
53, and
HCDR3 set forth in SEQ ID NO:
27;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
28,
LCDR2 set forth in SEQ ID NO:
29, and
LCDR3 set forth in SEQ ID NO:
30;
or
(6) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
45,
HCDR2 set forth in SEQ ID NO:
46, and
HCDR3 set forth in SEQ ID NO:
3;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
4,
LCDR2 set forth in SEQ ID NO:
5, and
LCDR3 set forth in SEQ ID NO:
6;
or
(7) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
58,
HCDR2 set forth in SEQ ID NO:
48, and
HCDR3 set forth in SEQ ID NO:
33;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
44,
LCDR2 set forth in SEQ ID NO:
35, and
LCDR3 set forth in SEQ ID NO:
36;
or
(8) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
49,
HCDR2 set forth in SEQ ID NO:
48, and
HCDR3 set forth in SEQ ID NO:
15;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
16,
LCDR2 set forth in SEQ ID NO:
17, and
LCDR3 set forth in SEQ ID NO:
18;
wherein the CDR sequences are identified based on the Chothia numbering scheme.

239 more elements

A chimeric antigen receptor (CAR), wherein the antigen-binding domain of the chimeric antigen receptor contains an antibody single-chain variable region sequence (scFv) targeting DLL3, and wherein the heavy chain variable region and light chain variable region of the scFv comprise complementarity determining regions (CDRs) selected from the group consisting of:

(1) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
37,
HCDR2 set forth in SEQ ID NO:
38, and
HCDR3 set forth in SEQ ID NO:
39;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
40,
LCDR2 set forth in SEQ ID NO:
41, and
LCDR3 set forth in SEQ ID NO:
42;
or
(2) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
7,
HCDR2 set forth in SEQ ID NO:
8, and
HCDR3 set forth in SEQ ID NO:
9;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
10,
LCDR2 set forth in SEQ ID NO:
11, and
LCDR3 set forth in SEQ ID NO:
12;
or
(3) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
19,
HCDR2 set forth in SEQ ID NO:
20, and
HCDR3 set forth in SEQ ID NO:
21;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
22,
LCDR2 set forth in SEQ ID NO:
23, and
LCDR3 set forth in SEQ ID NO:
24;
or
(4) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
31,
HCDR2 set forth in SEQ ID NO:
32, and
HCDR3 set forth in SEQ ID NO:
33;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
34,
LCDR2 set forth in SEQ ID NO:
35, and
LCDR3 set forth in SEQ ID NO:
36;
or
(5) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
25,
HCDR2 set forth in SEQ ID NO:
26, and
HCDR3 set forth in SEQ ID NO:
27;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
28,
LCDR2 set forth in SEQ ID NO:
29, and
LCDR3 set forth in SEQ ID NO:
30;
or
(6) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
1,
HCDR2 set forth in SEQ ID NO:
2, and
HCDR3 set forth in SEQ ID NO:
3;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
4,
LCDR2 set forth in SEQ ID NO:
5, and
LCDR3 set forth in SEQ ID NO:
6;
or
(7) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
13,
HCDR2 set forth in SEQ ID NO:
43, and
HCDR3 set forth in SEQ ID NO:
33;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
44,
LCDR2 set forth in SEQ ID NO:
35, and
LCDR3 set forth in SEQ ID NO:
36;
or
(8) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
13,
HCDR2 set forth in SEQ ID NO:
14, and
HCDR3 set forth in SEQ ID NO:
15;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
16,
LCDR2 set forth in SEQ ID NO:
17, and
LCDR3 set forth in SEQ ID NO:
18;
wherein the CDR sequences are identified based on the Kabat numbering scheme;
or
the heavy chain variable region and light chain variable region of the scFv comprise complementarity determining regions (CDRs) selected from the group consisting of:
(1) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
56,
HCDR2 set forth in SEQ ID NO:
57, and
HCDR3 set forth in SEQ ID NO:
39;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
40,
LCDR2 set forth in SEQ ID NO:
41, and
LCDR3 set forth in SEQ ID NO:
42;
or
(2) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
47,
HCDR2 set forth in SEQ ID NO:
48, and
HCDR3 set forth in SEQ ID NO:
9;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
10,
LCDR2 set forth in SEQ ID NO:
11, and
LCDR3 set forth in SEQ ID NO:
12;
or
(3) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
50,
HCDR2 set forth in SEQ ID NO:
51, and
HCDR3 set forth in SEQ ID NO:
21;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
22,
LCDR2 set forth in SEQ ID NO:
23, and
LCDR3 set forth in SEQ ID NO:
24;
or
(4) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
54,
HCDR2 set forth in SEQ ID NO:
55, and
HCDR3 set forth in SEQ ID NO:
33;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
34,
LCDR2 set forth in SEQ ID NO:
35, and
LCDR3 set forth in SEQ ID NO:
36;
or
(5) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
52,
HCDR2 set forth in SEQ ID NO:
53, and
HCDR3 set forth in SEQ ID NO:
27;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
28,
LCDR2 set forth in SEQ ID NO:
29, and
LCDR3 set forth in SEQ ID NO:
30;
or
(6) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
45,
HCDR2 set forth in SEQ ID NO:
46, and
HCDR3 set forth in SEQ ID NO:
3;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
4,
LCDR2 set forth in SEQ ID NO:
5, and
LCDR3 set forth in SEQ ID NO:
6;
or
(7) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
58,
HCDR2 set forth in SEQ ID NO:
48, and
HCDR3 set forth in SEQ ID NO:
33;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
44,
LCDR2 set forth in SEQ ID NO:
35, and
LCDR3 set forth in SEQ ID NO:
36;
or
(8) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
49,
HCDR2 set forth in SEQ ID NO:
48, and
HCDR3 set forth in SEQ ID NO:
15;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
16,
LCDR2 set forth in SEQ ID NO:
17, and
LCDR3 set forth in SEQ ID NO:
18;
wherein the CDR sequences are identified based on the Chothia numbering scheme.

239 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/485,025Filed 30 Apr 2024
Priority: CN 202310557360.017 May 2023
Published: 8 Oct 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

C07K 16/18
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material from animals or humans
A61K 47/6813
The drug being a protein or peptide, e.g. transferrin or bleomycin: the drug being a peptidic cytokine, e.g. an interleukin or interferon
A61K 47/6843
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a material from…
A61K 49/0002
Preparations for testing in vivo: general or multifunctional contrast agents, e.g. chelated agents

Family

No related US applications are recorded in the indexed filing history.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

(1) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
37,
HCDR2 set forth in SEQ ID NO:
38, and
HCDR3 set forth in SEQ ID NO:
39;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
40,
LCDR2 set forth in SEQ ID NO:
41, and
LCDR3 set forth in SEQ ID NO:
42;
or
(2) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
7,
HCDR2 set forth in SEQ ID NO:
8, and
HCDR3 set forth in SEQ ID NO:
9;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
10,
LCDR2 set forth in SEQ ID NO:
11, and
LCDR3 set forth in SEQ ID NO:
12;
or
(3) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
19,
HCDR2 set forth in SEQ ID NO:
20, and
HCDR3 set forth in SEQ ID NO:
21;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
22,
LCDR2 set forth in SEQ ID NO:
23, and
LCDR3 set forth in SEQ ID NO:
24;
or
(4) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
31,
HCDR2 set forth in SEQ ID NO:
32, and
HCDR3 set forth in SEQ ID NO:
33;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
34,
LCDR2 set forth in SEQ ID NO:
35, and
LCDR3 set forth in SEQ ID NO:
36;
or
(5) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
25,
HCDR2 set forth in SEQ ID NO:
26, and
HCDR3 set forth in SEQ ID NO:
27;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
28,
LCDR2 set forth in SEQ ID NO:
29, and
LCDR3 set forth in SEQ ID NO:
30;
or
(6) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
1,
HCDR2 set forth in SEQ ID NO:
2, and
HCDR3 set forth in SEQ ID NO:
3;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
4,
LCDR2 set forth in SEQ ID NO:
5, and
LCDR3 set forth in SEQ ID NO:
6;
or
(7) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
13,
HCDR2 set forth in SEQ ID NO:
43, and
HCDR3 set forth in SEQ ID NO:
33;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
44,
LCDR2 set forth in SEQ ID NO:
35, and
LCDR3 set forth in SEQ ID NO:
36;
or
(8) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
13,
HCDR2 set forth in SEQ ID NO:
14, and
HCDR3 set forth in SEQ ID NO:
15;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
16,
LCDR2 set forth in SEQ ID NO:
17, and
LCDR3 set forth in SEQ ID NO:
18;
wherein the CDR sequences are identified based on the Kabat numbering scheme;
or
the heavy chain variable region and light chain variable region of the antibody or antigen-binding fragment thereof comprise complementarity determining regions (CDRs) selected from the group consisting of:
(1) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
56,
HCDR2 set forth in SEQ ID NO:
57, and
HCDR3 set forth in SEQ ID NO:
39;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
40,
LCDR2 set forth in SEQ ID NO:
41, and
LCDR3 set forth in SEQ ID NO:
42;
or
(2) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
47,
HCDR2 set forth in SEQ ID NO:
48, and
HCDR3 set forth in SEQ ID NO:
9;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
10,
LCDR2 set forth in SEQ ID NO:
11, and
LCDR3 set forth in SEQ ID NO:
12;
or
(3) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
50,
HCDR2 set forth in SEQ ID NO:
51, and
HCDR3 set forth in SEQ ID NO:
21;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
22,
LCDR2 set forth in SEQ ID NO:
23, and
LCDR3 set forth in SEQ ID NO:
24;
or
(4) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
54,
HCDR2 set forth in SEQ ID NO:
55, and
HCDR3 set forth in SEQ ID NO:
33;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
34,
LCDR2 set forth in SEQ ID NO:
35, and
LCDR3 set forth in SEQ ID NO:
36;
or
(5) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
52,
HCDR2 set forth in SEQ ID NO:
53, and
HCDR3 set forth in SEQ ID NO:
27;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
28,
LCDR2 set forth in SEQ ID NO:
29, and
LCDR3 set forth in SEQ ID NO:
30;
or
(6) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
45,
HCDR2 set forth in SEQ ID NO:
46, and
HCDR3 set forth in SEQ ID NO:
3;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
4,
LCDR2 set forth in SEQ ID NO:
5, and
LCDR3 set forth in SEQ ID NO:
6;
or
(7) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
58,
HCDR2 set forth in SEQ ID NO:
48, and
HCDR3 set forth in SEQ ID NO:
33;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
44,
LCDR2 set forth in SEQ ID NO:
35, and
LCDR3 set forth in SEQ ID NO:
36;
or
(8) the heavy chain variable region comprises the following complementarity determining regions (CDRs):
HCDR1 set forth in SEQ ID NO:
49,
HCDR2 set forth in SEQ ID NO:
48, and
HCDR3 set forth in SEQ ID NO:
15;
and the light chain variable region comprises the following complementarity determining regions (CDRs):
LCDR1 set forth in SEQ ID NO:
16,
LCDR2 set forth in SEQ ID NO:
17, and
LCDR3 set forth in SEQ ID NO:
18;
wherein the CDR sequences are identified based on the Chothia numbering scheme.

239 more elements

Facts

Application

19/485,025Filed 30 Apr 2024

Priority

CN 202310557360.017 May 2023

Published

8 Oct 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

C07K 16/18
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material from animals or humans
A61K 47/6813
The drug being a protein or peptide, e.g. transferrin or bleomycin: the drug being a peptidic cytokine, e.g. an interleukin or interferon
A61K 47/6843
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a material from…
A61K 49/0002
Preparations for testing in vivo: general or multifunctional contrast agents, e.g. chelated agents